GlobalData on MSN10h
Valneva hits 2024 sales target but plans lower cash burn in 2025
Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...
The National Law Review8h
Executive Order: One Voice for America’s Foreign Relations
President Donald Trump announced an executive order indicating to consular officers and foreign officers that “failure to faithfully implement the President’s policy is grounds for professional ...